BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 24496381)

  • 1. BET bromodomain proteins are required for glioblastoma cell proliferation.
    Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
    Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.
    Hishiki K; Akiyama M; Kanegae Y; Ozaki K; Ohta M; Tsuchitani E; Kaito K; Yamada H
    Leuk Res; 2018 Nov; 74():57-63. PubMed ID: 30300821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction.
    Yao Z; Yang S; Zhao H; Yang H; Jiang X
    Cancer Gene Ther; 2020 Apr; 27(3-4):226-234. PubMed ID: 30518782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth.
    Niu N; Shao R; Yan G; Zou W
    J Biol Chem; 2016 Dec; 291(52):26647-26657. PubMed ID: 27821592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers.
    Long J; Li B; Rodriguez-Blanco J; Pastori C; Volmar CH; Wahlestedt C; Capobianco A; Bai F; Pei XH; Ayad NG; Robbins DJ
    J Biol Chem; 2014 Dec; 289(51):35494-502. PubMed ID: 25355313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.
    Boehm D; Calvanese V; Dar RD; Xing S; Schroeder S; Martins L; Aull K; Li PC; Planelles V; Bradner JE; Zhou MM; Siliciano RF; Weinberger L; Verdin E; Ott M
    Cell Cycle; 2013 Feb; 12(3):452-62. PubMed ID: 23255218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma.
    Xu L; Chen Y; Mayakonda A; Koh L; Chong YK; Buckley DL; Sandanaraj E; Lim SW; Lin RY; Ke XY; Huang ML; Chen J; Sun W; Wang LZ; Goh BC; Dinh HQ; Kappei D; Winter GE; Ding LW; Ang BT; Berman BP; Bradner JE; Tang C; Koeffler HP
    Proc Natl Acad Sci U S A; 2018 May; 115(22):E5086-E5095. PubMed ID: 29764999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis.
    Xiong C; Masucci MV; Zhou X; Liu N; Zang X; Tolbert E; Zhao TC; Zhuang S
    Oncotarget; 2016 Oct; 7(43):69291-69308. PubMed ID: 27732564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRD4: New hope in the battle against glioblastoma.
    Duan W; Yu M; Chen J
    Pharmacol Res; 2023 May; 191():106767. PubMed ID: 37061146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts.
    Klein K; Kabala PA; Grabiec AM; Gay RE; Kolling C; Lin LL; Gay S; Tak PP; Prinjha RK; Ospelt C; Reedquist KA
    Ann Rheum Dis; 2016 Feb; 75(2):422-9. PubMed ID: 25467295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma.
    Kfoury N; Qi Z; Prager BC; Wilkinson MN; Broestl L; Berrett KC; Moudgil A; Sankararaman S; Chen X; Gertz J; Rich JN; Mitra RD; Rubin JB
    Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33850013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
    Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
    Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
    Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
    Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
    Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
    Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
    Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
    Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
    Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
    Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.